HNF4A and metabolic dysfunction-associated steatohepatitis: To assess whether CK19+HNF4α+ cells were also present in patients with severe liver injury, we analyzed biopsies from healthy livers and 11 different liver disease indications (Supplementary Table 3), including NASH and viral hepatitis with and without cirrhosis, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), acute liver failure, autoimmune hepatitis (AIH) and alcoholic steatohepatitis (ASH) with cirrhosis (ASH cirrhosis).